Neuroblastoma organoid construction formula and method thereof
By developing formulations and methods for neuroblastoma organoids, the problems of time-consuming and costly existing models have been solved, enabling efficient personalized drug screening and efficacy evaluation, and improving the survival time and quality of life for children with neuroblastoma.
Patent Information
- Application Number
- CN202411241203.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-22
AI Technical Summary
Existing mouse xenograft models for human tissue transplantation are costly, time-consuming, and have a low success rate when screening chemotherapy drugs for neuroblastoma, making it difficult to meet the need for rapid and effective drug screening.
A formulation for constructing neuroblastoma organoids is provided, comprising a sample culture medium, a washing solution, and a digestion solution of specific components, for constructing neuroblastoma organoids through washing, digestion, and culture steps, and for 3D culture using Matrigel to simulate the extracellular matrix.
It improved the survival rate and maintenance of tumor heterogeneity of neuroblastoma organoids, realized an efficient platform for personalized drug screening and efficacy evaluation, and improved the survival time and quality of life of children.
Smart Images

Figure CN118995609A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cell culture, in particular to a formula for constructing neuroblastoma organoids, and also to a method for culturing neuroblastoma organoids using the formula. Background Art
[0002] Neuroblastoma is the most common extracranial solid malignant tumor in children at this stage. It has an insidious onset, high malignancy, rapid disease progression, and early distant metastasis. The 5-year survival rate of high-risk children is only 50%, and the mortality rate is 15% of childhood malignant tumors. Children with medium and low risk are mainly treated with surgical resection combined with postoperative chemotherapy. Children in the high-risk group are treated with a three-stage multidisciplinary combined treatment (MDT) including an induction phase (combined chemotherapy and surgical resection), a consolidation phase (autologous hematopoietic stem cell transplantation and radiotherapy), and a maintenance phase (retinoic acid, chemotherapy, etc.). Regardless of the stage to which the child's disease progresses, combined chemotherapy intervention is required. At this point, choosing the chemotherapy drug that best suits the individual patient is a key part of postoperative treatment.
[0003] Clinically, mice are often used to establish patient-derived xenografts (PDX) models, that is, tumor tissue from patients is transplanted into severely immunodeficient mice to grow into transplanted tumors. When they grow to a certain size, they are removed and transplanted into a new batch of mice, and the operation is repeated for more generations until the dosage for drug screening and efficacy evaluation is met. The PDX model can retain the growth characteristics of the parental tumor and maintain heterogeneity, but its high cost, long time consumption, and low success rate are its inevitable disadvantages. For children with neuroblastoma whose disease progresses rapidly, it is urgent to find a fast and effective drug screening and efficacy evaluation model.
[0004] In 2009, Hans Clevers cultivated intestinal organoids from LGR5+ intestinal stem cells, which is considered the "first year of organoids". With the continuous development of the organoid field, different from 2D cell culture technology, 3D organoid model technology can further achieve personalized models from tumor tissues with higher success rates. Tumor organoids retain the key histopathological, genetic and phenotypic characteristics of the parent tumor, giving them the same sensitivity to chemotherapy drugs and targeted drugs as the mother, thereby realizing the screening of personalized medication plans.
[0005] Tumor organoids, as "drug test substitutes", can not only conduct personalized drug screening for clinical patients, but also provide scientific researchers with a more representative platform for simulating tumor heterogeneity and tumor microenvironment interactions in vitro, laying the foundation for overcoming the problem of cancer at an early date. Summary of the invention
[0006] In view of this, one of the objects of the present invention is to provide a neuroblastoma organoid construction formula; a second object of the present invention is to provide a method for constructing neuroblastoma organoids using the neuroblastoma organoid construction formula.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] 1. A formula for constructing neuroblastoma organoids, the formula comprising a sample culture medium, the concentrations of the components of the sample culture medium being as follows: 1-5% volume fraction of Glutamax, 0.1-2% volume fraction of penicillin-streptomycin-amphotericin B, 0.5-2.5% volume fraction of HEPES, 1-5% volume fraction of B27, 1-5% volume fraction of N2, 5-30ng / ml EGF, 5-50ng / ml bFGF, 5-20% volume fraction of MEM non-essential amino acid solution, 20-100μM 2-mercaptoethanol, 5-20% volume of FBS, 50-200μg / ml Promicin, and 500-2000U / ml LIF are added to Advaced DMEM / F12.
[0009] Preferably, the present invention further comprises a sample cleaning solution, wherein the concentrations of the components of the sample cleaning solution are as follows: 0.1-0.5 mg / ml hyaluronidase, 0.1-5 U / ml elastase, 0.05-0.5 mg / ml deoxyribonucleotidase I, 10-50 μM Z-VAD(OH)-FMK, and 0.1-3% volume of penicillin-streptomycin-amphotericin B are added to 1×DPBS.
[0010] Preferably, the present invention further comprises a sample digestion solution, wherein the concentrations of the components of the sample digestion solution are as follows: collagenase IV is added to Advaced DMEM / F12 to a final concentration of 0.5-2 mg / ml, deoxyribonucleotidase I is added to a final concentration of 0.05-0.5 mg / ml, and Z-VAD(OH)-FMK is added to a final concentration of 10-50 μM.
[0011] 2. A method for constructing neuroblastoma organoids using the neuroblastoma organoid construction formula, comprising the following method:
[0012] (1) Take a neuroblastoma tumor tissue sample and immerse it in a sample cleaning solution for cleaning;
[0013] (2) After washing, the sample is chopped and then digested with sample digestion solution. After the digestion is terminated, the precipitate is collected and resuspended with sample culture medium. The cell suspension is then thoroughly mixed with Matrigel and the mixture is evenly dropped into the well plate and allowed to stand to solidify the matrix gel;
[0014] (3) Remove the well plate, add neuroblastoma organoid culture medium, and place it in an incubator for continuous culture for 7 to 20 days.
[0015] Preferably, in step (1) of the present invention, the sample cleaning solution is added in an amount of 10 times the sample volume.
[0016] Preferably, in step (1), the cleaning is performed by immersing the neuroblastoma tumor tissue sample in a sample cleaning solution, shaking and incubating on a constant temperature shaker at 200 rpm and 25° C. for 60 minutes, during which the sample cleaning solution is replaced every 20 minutes.
[0017] Preferably, in step (2), the cutting is to cut the tissue into pieces of 1 mm 3 Small pieces around.
[0018] Preferably, in step (2), the digestion is performed by adding the chopped tissue to 5 times the volume of sample digestion solution, incubating at 200 rpm, 37°C constant temperature shaker for 5-10 minutes, and terminating the digestion with 10 times the volume of sample digestion solution Advanced DMEM / F12.
[0019] Preferably, in step (2), the collecting of the precipitate is performed by centrifuging at 4°C, 500×g, for 10 min, discarding the supernatant, and collecting the sample precipitate.
[0020] Preferably, in step (2), the step of allowing the matrix gel to solidify is allowing the matrix gel to solidify in a 37° C. incubator for 30 minutes.
[0021] The beneficial effect of the present invention is that the present invention provides a formula for constructing neuroblastoma organoids, wherein the sample cleaning solution and the sample digestion solution in the formula contain Z-VAD(OH)-FMK, and Z-VAD(OH)-FMK is a carboxyl compound form of Z-VAD-FMK. The hydrophilic carboxyl group can freely enter cells in a water-soluble environment, inhibit the caspase apoptosis pathway, and thus improve the survival rate of neuroblastoma organoids.
[0022] The sample washing solution contains elastase, which can hydrolyze and remove the reticular fibers, namely elastin, in the fibrotic tissue when the tumor sample is incubated in the washing solution to release the tumor cells.
[0023] The cleaning solution contains hyaluronidase, which can hydrolyze and remove hyaluronic acid in the sample and release tumor cells when the tumor sample is incubated in the cleaning solution.
[0024] Through the action of each component, technical barriers have been overcome, enabling precision medicine and improving the survival time and quality of life of children with neuroblastoma. The neuroblastoma construction method provided by the present invention can efficiently transform surgically removed tumor samples into neuroblastoma organoids, using Matrigel to simulate the extracellular matrix to provide 3D support for the samples, and continuous cultivation can better maintain the stemness of tumor stem cells and maintain the tumor heterogeneity of organoids. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:
[0026] Figure 1 The morphology of the organoids in Example 2 24 hours and 10 days after inoculation;
[0027] Figure 2 The morphology of the organoids in Example 3 24 hours and 10 days after inoculation;
[0028] Figure 3 This is the morphology of the organoid in comparative example 1 24 hours and 10 days after inoculation. DETAILED DESCRIPTION
[0029] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0030] Example 1. Neuroblastoma cleaning solution and culture medium
[0031] A neuroblastoma sample washing solution, comprising the following components: 0.2 mg / ml hyaluronidase, 4 U / ml elastase, 0.1 mg / ml deoxyribonucleotidase I, 40 μM Z-VAD(OH)-FMK, and 2% volume of penicillin-streptomycin-amphotericin B, wherein the above components are dissolved in 1×DPBS.
[0032] A neuroblastoma sample digestion solution, the digestion solution contains the following components: 1 mg / ml collagenase IV, 0.1 mg / ml deoxyribonucleotidase I, 40 μM Z-VAD(OH)-FMK, and the above components are dissolved in Advaced DMEM / F12.
[0033] A neuroblastoma organoid culture medium, comprising: adding 1% volume of Glutamax, 1% volume of Penicillin-Streptomycin-Amphotericin B, 1% volume of HEPES, 2% volume of B27, 1% volume of N2, 20 ng / ml EGF, 40 ng / ml bFGF, 5% volume of non-essential amino acids, 55 μM 2-mercaptoethanol, 10% volume of FBS, 100 μg / ml Promicin, and 1000 U / ml LIF to Advaced DMEM / F12. In this embodiment, the non-essential amino acids were purchased from Thermo Company with a product number of 11140050, containing 750 mg / L of Glycine, 890 mg / L of L-Alanine, 1320 mg / L of L-Asparagine, 1330 mg / L of L-Aspartic acid, 1470 mg / L of L-Glutamic Acid, 1150 mg / L of L-Proline, and 1050 mg / L of L-Serine.
[0034] Example 2: Construction of neuroblastoma organoids
[0035] Use the above reagents to complete the construction of neuroblastoma organoids. The specific steps are as follows:
[0036] (1) Take a neuroblastoma tumor tissue sample from a child who underwent surgical resection, immerse it in a neuroblastoma sample cleaning solution with a volume 10 times that of the sample, and incubate it in a constant temperature shaker at 200 rpm and 25°C for 60 min, during which the sample cleaning solution is replaced every 20 min;
[0037] (2) Collect the cleaned sample and mince it into 1 mm pieces using a sterile scalpel. 3 Transfer the small pieces to 5 times the sample volume of neuroblastoma sample digestion solution, incubate at 200 rpm, 37°C constant temperature shaker for 5-10 min, and terminate the digestion with 10 times the sample digestion solution volume of Advaced DMEM / F12;
[0038] (3) Centrifuge at 4°C, 500 × g, 10 min, discard the supernatant, collect the sample pellet, and add organoid culture medium to form a cell suspension;
[0039] (4) Mix the cell suspension and Matrigel thoroughly, drip the mixture evenly into the well plate at a rate of 30-40 μl / gel drop, and incubate at 37°C for 30 min to allow the Matrigel to solidify;
[0040] (5) Remove the well plate, add neuroblastoma organoid culture medium to the well plate, and place it in an incubator for continuous culture. The early morphology of neuroblastoma organoids can be formed in about 24 hours, and the typical morphology of neuroblastoma organoids can be observed in about 7 to 20 days;
[0041] (6) Continue culturing in a 37°C incubator and change the medium every 3 days.
[0042] The morphology of organoids 24 hours and 10 days after inoculation Figure 1 As shown; the results show that compared with the comparative example, the neuroblastoma organoids obtained in Example 1 constructed according to the present method are more in number and larger in size.
[0043] Example 3
[0044] A neuroblastoma sample washing solution, comprising the following components: 0.4 mg / ml hyaluronidase, 2 U / ml elastase, 0.2 mg / ml deoxyribonucleotidase I, 30 μM Z-VAD(OH)-FMK, 1% volume of penicillin-streptomycin-amphotericin B, and the above components are dissolved in 1×DPBS.
[0045] A neuroblastoma sample digestion solution, the digestion solution contains the following components: 0.8 mg / ml collagenase IV, 0.2 mg / ml deoxyribonucleotidase I, 30 μM Z-VAD(OH)-FMK, and the above components are dissolved in Advaced DMEM / F12.
[0046] A neuroblastoma organoid culture medium, comprising: adding 0.8% volume Glutamax, 1.5% volume Penicillin-Streptomycin-Amphotericin B, 2% volume HEPES, 1.5% volume B27, 1.5% volume N2, 30 ng / ml EGF, 30 ng / ml bFGF, 3% volume non-essential amino acids, 60 μM 2-mercaptoethanol, 5% volume FBS, 80 μg / ml Promicin, and 2000 U / ml LIF to Advaced DMEM / F12.
[0047] The above cleaning solution and culture medium were used to complete the construction of organoids. The specific steps were the same as those in Example 2, except that the cleaning solution, digestion solution and culture medium used were different from those in Example 1. The results showed that the number of neuroblastoma organoids constructed by this method was large and the volume was large.
[0048] Comparative Example 1
[0049] A washing solution for a neuroblastoma sample, the washing solution comprising the following components: 2% volume of penicillin-streptomycin-amphotericin B, the above components being dissolved in 1×DPBS;
[0050] A neuroblastoma sample digestion solution, the digestion solution containing the following components: 1 mg / ml collagenase IV, 0.1 mg / ml deoxyribonucleotidase I, the above components are dissolved in Advanced DMEM / F12;
[0051] A neuroblastoma organoid culture medium, same as in Example 1;
[0052] The organoids were constructed using the cleaning solution and culture medium, and the specific operation was the same as in Example 2 to complete the organoid construction;
[0053] The morphology of organoids 24 hours and 10 days after inoculation Figure 3 As shown; the results showed that the neuroblastoma organoids obtained by this comparative example were small in number and size, and suffered from severe apoptosis during subsequent culture.
[0054] The sample cleaning solution and sample digestion solution of the present invention contain Z-VAD(OH)-FMK, which is a pan-caspase inhibitor. Preclinical studies over the years have shown that caspases mainly act as mediators of inflammation and apoptosis in various pathologies. Other studies have shown that pretreatment of Hela cells with 40 μM Z-VAD-FMK for 30 minutes can reverse the apoptotic effect of total saponins on Hela cells. Z-VAD(OH)-FMK is a carboxyl compound form of Z-VAD-FMK. The hydrophilic carboxyl group can freely enter cells in a water-soluble environment, inhibit the caspase apoptosis pathway, and thus improve the survival rate of neuroblastoma organoids.
[0055] The fibrotic matrix of the tumor microenvironment can resist the infiltration of immune cells, thereby promoting tumor cells to complete immune escape. Components of the fibrotic matrix, such as collagen I and IV, fibronectin, laminin, hyaluronic acid, and elastin, will reduce the efficiency of organoid separation when performing organoid separation. Neuroblastoma tumor samples are often accompanied by varying degrees of fibrosis. Elastase can hydrolyze elastin. The sample cleaning solution of this method contains elastase, which can hydrolyze and remove the reticular fibers in the fibrotic tissue, namely elastin, when the tumor sample is incubated and cleaned in the cleaning solution, releasing tumor cells.
[0056] Hyaluronidase is a general term for a class of enzymes that can hydrolyze hyaluronic acid. The hyaluronic acid in the tumor matrix forms a large amount of mucus with certain glycoproteins. When tumor samples are processed, a large amount of foam is often formed to wrap the samples, resulting in reduced sample collection efficiency. The sample cleaning solution of this method contains hyaluronidase, which can hydrolyze and remove the hyaluronic acid in the sample when the cleaning solution is incubated to clean the tumor sample, thereby releasing the tumor cells.
[0057] Lysis of dead cells will release DNA into the sample, and a large amount of DNA will wrap the sample, reducing the sample recovery rate. In this method, deoxyribonucleotidase I is added to the sample cleaning solution, which can effectively degrade the DNA released from the sample and improve the sample recovery efficiency.
[0058] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A formulation for constructing neuroblastoma organoids, characterized in that: The formula includes a sample culture medium, and the concentrations of the components of the sample culture medium are as follows: 1-5% volume fraction of Glutamax, 0.1-2% volume fraction of penicillin-streptomycin-amphotericin B, 0.5-2.5% volume fraction of HEPES, 1-5% volume fraction of B27, 1-5% volume fraction of N2, 5-30ng / ml EGF, 5-50ng / ml bFGF, 5-20% volume fraction of MEM non-essential amino acid solution, 20-100μM 2-mercaptoethanol, 5-20% volume of FBS, 50-200μg / ml Promicin, and 500-2000U / ml LIF are added to Advaced DMEM / F12.
2. A neuroblastoma organoid construction formula according to claim 1, characterized in that: It also includes a sample washing solution, wherein the concentrations of the components of the sample washing solution are as follows: 0.1-0.5 mg / ml hyaluronidase, 0.1-5 U / ml elastase, 0.05-0.5 mg / ml deoxyribonucleotidase I, 10-50 μM Z-VAD(OH)-FMK, and 0.1-3% volume of penicillin-streptomycin-amphotericin B are added to 1×DPBS.
3. A neuroblastoma organoid construction formula according to claim 1, characterized in that: The sample digestion solution also includes a sample digestion solution, wherein the concentrations of the components of the sample digestion solution are as follows: collagenase IV is added to Advaced DMEM / F12 to a final concentration of 0.5-2 mg / ml, deoxyribonucleotidase I is added to a final concentration of 0.05-0.5 mg / ml, and Z-VAD(OH)-FMK is added to a final concentration of 10-50 μM.
4. A method for constructing neuroblastoma organoids using the neuroblastoma organoid construction formula according to any one of claims 1 to 3, characterized in that: The following methods are included: (1) Taking a neuroblastoma tumor tissue sample and immersing it in a sample cleaning solution for cleaning; (2) After washing, the sample is chopped and then digested with sample digestion solution. After the digestion is terminated, the precipitate is collected and resuspended with sample culture medium. The cell suspension is then thoroughly mixed with Matrigel and the mixture is evenly dropped into the well plate and allowed to stand to solidify the matrix gel; (3) Remove the well plate, add neuroblastoma organoid culture medium, and place it in an incubator for continuous culture for 7 to 20 days.
5. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (1), the sample cleaning solution is added in an amount of 10 times the sample volume.
6. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (1), the cleaning is performed by immersing the neuroblastoma tumor tissue sample in a sample cleaning solution, shaking and incubating on a constant temperature shaker at 200 rpm and 25° C. for 60 minutes, during which the sample cleaning solution is replaced every 20 minutes.
7. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (2), the cutting is to cut the tissue into pieces of 1 mm 3 Small pieces around.
8. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (2), the digestion is performed by adding the chopped tissue into 5 times the volume of sample digestion solution, incubating at 200 rpm, 37°C constant temperature shaker for 5-10 minutes, and using 10 times the volume of sample digestion solution Advanced DMEM / F12 to terminate the digestion.
9. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (2), the precipitate is collected by centrifuging at 4°C, 500×g, for 10 min, discarding the supernatant, and collecting the sample precipitate.
10. The method for constructing neuroblastoma organoids according to the neuroblastoma organoid construction formula of claim 4, characterized in that: In step (2), the step of allowing the matrix gel to solidify is to allow the matrix gel to solidify by allowing the matrix gel to solidify in a 37° C. incubator for 30 minutes.
Citation Information
Cited By
Biological ink, in-vitro humanized neural model and application of biological ink and in-vitro humanized neural model in construction of opioid drug classification prediction model and dose-effect relationship
CN120272427A
Bio-ink, in-vitro humanized neural model and its application in constructing opioid drug classification prediction model and dose-effect relationship
CN120272427B
